论文部分内容阅读
在人类个体发展史上,4—5个月胎龄的胎肝中造血干细胞最丰富,T淋巴细胞只占1～2％,是理想的造血干细胞来源。输注给再生障碍性贫血等骨髓衰竭患者有一定的疗效,且较少发生抗宿主病(GVHD),因此胎肝细胞移植比同种骨髓移植更有前途,已为不少学者所肯定。1985年我们对12例(共23例次)再障患者进行胎肝细胞输注(FLT)治疗中,其中近期疗效明显进步3例,缓解3例,稳定2例,总有效率66.7％。本文就我们制备胎肝细胞悬液的初步实践谈几点体会。
In the history of human development, 4-7 months fetal liver hematopoietic stem cells in the most abundant, T lymphocytes only 1 to 2%, is the ideal source of hematopoietic stem cells. Infusion of aplastic anemia and other bone marrow failure patients have a certain effect, and less incidence of anti-host disease (GVHD), fetal liver cell transplantation is more promising than allogeneic bone marrow transplantation, has been recognized by many scholars. In 1985, we treated 12 patients (23 cases) with aplastic anemia in fetal liver fibrosis (FLT). Among them, 3 cases were significantly improved in the short term, 3 cases were relieved and 2 cases were stable. The total effective rate was 66.7%. This article on our preparation of fetal liver cell suspension to talk about the initial practice of a few experiences.